Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | CNR2 | P34972 | 9/20 | 0.38 |
| ▸ | CNR1 | P21554 | 7/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21987827 | 1.00 | PPARA (0.44) | PPARAPPARGPPARDCNR2CNR1 | |
| SCHEMBL20471317 | 0.90 | SOAT1 (0.44) | PPARAPPARGPPARDSOAT1 | |
| SCHEMBL20471319 | 0.90 | SOAT1 (0.44) | PPARAPPARGPPARDSOAT1 | |
| SCHEMBL28387498 | 0.88 | SOAT1 (0.47) | PPARAPPARGPPARDSOAT1 | |
| SCHEMBL10300838 | 0.85 | CNR2 (0.51) | PPARAPPARGPPARDCNR2CNR1 | |
| SCHEMBL1532484 | 0.85 | PPARA (0.55) | PPARAPPARGPPARDCNR2CNR1 | |
| SCHEMBL1532486 | 0.85 | PPARA (0.55) | PPARAPPARGPPARDCNR2CNR1 | |
| SCHEMBL2382741 | 0.79 | TSHR (0.46) | PPARAPPARGPPARDCNR2CNR1 | |
| SCHEMBL2382740 | 0.79 | TSHR (0.46) | PPARAPPARGPPARDCNR2CNR1 | |
| SCHEMBL3509181 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10335504-B2 | Heterocyclic molecules for biomedical imaging and therapeutic applications | WASHINGTON UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10335504-B2 | Heterocyclic molecules for biomedical imaging and therapeutic applications | APP, PSEN1, BACE1 | PPARA 2347/4885PPARG 2028/4885PPARD 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.